Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 169 full-time employees. The firm is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. The company focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.